Evaluation of efficacy and tolerability of levetiracetam as an add-on therapy in intractable epilepsy of children
Iranian Journal of Child Neurology,
Vol. 16 No. 2 (2022),
14 March 2022
,
Page 77-84
https://doi.org/10.22037/ijcn.v15i4.29028
Abstract
Objective: One-third of epilepsy of children is refractory and this study was conducted to evaluate efficacy and adverse events of levetiracetam as an add-on therapy in treatment of refractory epilepsy of children.
Materials & Methods: In a quasi- experimental study, seizures frequency and side effects of 314 children aged 1-14 years with refractory epilepsy who were referred to Pediatric Neurology Clinic of Shahid Sadoughi Medical Sciences University, Yazd, Iran and treated with levetiracetam for six months, were evaluated.
Results: 142 girls and 172 boys with mean age of 6.78±2.12 years were evaluated. At the end of six months of treatment with levetiracetam, 20% became seizure free, 28% had more than 50% decrease in seizure frequency, 38% did not have a notable change in seizure frequency and 14% experienced an increase in seizure frequency. Good response (stopping of all seizures or more than 50% reduction in seizure frequency) was seen in 51% of mixed type, 61% of myoclonic seizures, 64% of generalized tonic clonic seizures, 69 % of partial seizures, 100 % of tonic seizures and in 40 % of atonic seizures. Levetiracetam was significantly more effective in partial seizures, idiopathic epilepsies, children with normal developmental status and normal brain MRI.
Twelve children discontinued the treatment due to severe drowsiness, restlessness and exacerbation of seizures. Transient and mild side effects were seen in 9%(N=28) including somnolence, anorexia, fatigue, headache, ataxia and diplopia.
Conclusion: Levetiracetam could be considered as an efficient and safe adjunct therapy in treatment of refractory epilepsy in children.
- Epilepsy
- Refractory
- Children
- Levetiracetam
- Side effects
How to Cite
References
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55(4):475-82.
Mikati MA, Hani AJ. Seizures in childhood. Kliegman RM, Stanton BF, Schor NF, St. Geme JW, Behrman RE. Nelson Textbook of Pediatrics. Philadelphia, Elsevier 2016; 20 th edition, Pp.: 2823.
Berg AT. Identification of pharmacoresistant epilepsy. Neurol Clin 2009; 27(4):1003-13.
Incecik F, Hergüner MO, Altunbasak S . The efficacy and side effects of levetiracetam on refractory epilepsy in children. J Pediatr Neurosci 2012; 7(1):19-22.
Chen D, Bian H, Zhang L . A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy. Neuropsychiatr Dis Treat 2019, 11; 15:905-917.
Muramatsu K, Sawaura N, Ogata T, Makioka N, Tomita K, Motojima T, Ida K, Hazama K, Arakawa H. Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy. Brain Dev 2017; 39(3):231-235.
Rosati A, Ilvento L, Lucenteforte E, et al. Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. Epilepsia 2018; 59(2):297-314.
Chen J, Liu XM, Yue X, Chen SZ. The clinical efficacy and safety of levetiracetam add-on therapy for child refractory epilepsy. Eur Rev Med Pharmacol Sci 2016; 20(12):2689-94.
Kanemura H, Sano F, Tando T, Sugita K, Aihara M. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. Brain Dev 2013; 35(5):386-91.
Matsuo M, Fuji A, Matsuzaka T, Baba H, Toda K, Ono T, Tanaka S, Sato T, Moriuchi H. Effectiveness and safety of long-term levetiracetam treatment in patients with refractory epilepsy. No To Hattatsu 2015; 47(4):272-8. [Article in Japanese]
Tonekaboni SH, Ghazavi M, Karimzadeh P, Mahvelati F, Ghofrani M. Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial. Epilepsy Res 2010; 90(3):273-7.
Sheinberg R, Heyman E, Dagan Z, et al .Correlation between efficacy of levetiracetam and serum levels among children with refractory epilepsy. Pediatr Neurol 2015; 52(6): 624-8.
Kato T, Nakata M, Ide M, Saito K, Yoshida T, Awaya T, Heike T. Efficacy and tolerability of topiramate, lamotrigine, and levetiracetam in children with refractory epilepsy. No To Hattatsu 2015; 47(5):354-9. [Article in Japanese]
Kharod P, Mishra D, Juneja M . Drug-resistant epilepsy in Indian children at a tertiary-care public hospital. Childs Nerv Syst 2019; 35(5):775-778.
Opp J, Tuxhorn I, May T, Kluger G, Wiemer-Kruel A, Kurlemann G, Gross-Selbeck G, Rating D, Brandl U, Bettendorf U, Härtel C, Korn-Merker E. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14(7):476-84.
Doumbia-Ouattara M, Bourel-Ponchel E, Le Moing AG, Querne L, Delignières A, de Broca A, Berquin P . Experience with levetiracetam in the treatment of childhood refractory epilepsy.Arch Pediatr 2012; 19(1):3-8. [Article in French].
Lee YJ, Kang HC, Kim HD, Lee JS. Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. Pediatr Neurol 2010; 42(2):86-92.
Li S, Cao J, Xiao N, Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol 2010;25(5):609-13.
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018,10;91(2):82-90.
- Abstract Viewed: 651 times